Nice Quarter from A...
Health Care: Drugs
Affymax Inc. (AFFY: NASDAQ)
$10.78 -0.23 | -2.09%
02/09/12 - 01:52 PM ET
668.40K / 1.55M
Vol / Avg. Vol:11.07 / 11.01
Open / Prev. Close:10.72 - 11.11
Today's Range:3.93 - 11.13
52 Wk Range:66.57%
Performance YTD:TheStreet Rating:
Portfolios with AFFY
- Portfolio NameUser Type
- Usersimulator
- Contributor10 Biotech Stocks on Clinic...
- UserPART 5 JPMorgan 28th Annual...
- Usergrainey Portfolio 1
- Userjayacee Portfolio 1
- Usersupersonic_528
- Userrickwastaken Portfolio 1
- UserAffy
- ProCalypso Capital
- UserBRB Portfolio
Latest AFFY Headlines from TheStreet
- Adobe, Research In Motion: After-Hours Trading 12.15.11 | 05:12 pm
- Affymax's FDA Panel Live Blog 12.07.11 | 12:12 pm
- Affymax Stock Falls On Unusually High Volume (AFFY) 12.06.11 | 03:12 pm
- Affymax Rises on FDA Drug Review 12.05.11 | 08:12 am
- Biotech Stock Mailbag: Affymax 12.02.11 | 06:12 am
- Caterpillar, Exelixis, Crocs Are Big Market Movers 10.24.11 | 05:10 pm
- Affymax Stock Falls On Unusually High Volume (AFFY) 08.09.11 | 03:08 pm
- Affymax Stock Hits New 52-Week Low (AFFY) 08.08.11 | 10:08 am
- Insiders Trading GES, KW, AFFY 07.01.11 | 02:07 pm
- Affymax Stock Falls On Unusually High Volume (AFFY) 03.18.11 | 04:03 pm
Press Releases for AFFY
- Affymax To Present At 14th Annual BIO CEO & Investor Conference - Business Wire 02.08.12 | 04:02 pm
- Affymax Promotes Cynthia Smith To Vice President, Market Access And Commercial Development - Business Wire 02.02.12 | 04:02 pm
- Affymax To Webcast Analyst Briefing Event - Business Wire 01.04.12 | 05:01 pm
- Takeda And Affymax Provide Update On Peginesatide Commercialization Rights In Japan - Business Wire 12.15.11 | 04:12 pm
- FDA Advisory Committee Voted In Favor Of Benefit/Risk Profile For Peginesatide For Treatment Of Anemia In Chronic Kidney Disease Patients On Dialysis - Business Wire 12.07.11 | 07:12 pm
- Affymax And Takeda Report Additional Analyses Of Peginesatide Phase 3 Studies In Dialysis Patients At The American Society Of Nephrology’s Kidney Week 2011 - Business Wire 11.11.11 | 10:11 am
- Affymax® Reports Third Quarter 2011 Financial Results - Business Wire 11.09.11 | 08:11 am
- Affymax And Janssen Biotech Settle Patent Dispute - Business Wire 11.09.11 | 07:11 am
- Affymax Announces FDA Advisory Committee To Review Peginesatide - Business Wire 10.24.11 | 07:10 am
- Affymax And Takeda To Present Peginesatide Data At The American Society Of Nephrology Kidney Week 2011 - Business Wire 10.10.11 | 08:10 am
Partner Headlines for AFFY
- Affymax Spiking Higher on Heavy Volume - Benzinga 12.27.11 | 01:12 pm
- 7 Stocks With Unusual Options Activity - Seeking Alpha 12.09.11 | 09:12 am
- Q3 Micro-Cap Biotech Picks By The World's Largest Fund Managers - Seeking Alpha 12.08.11 | 09:12 am
- Company News for December 6, 2011 - Corporate Summary - Zacks 12.06.11 | 10:12 am
- Mid-Day Update: Stocks Sitting Higher as Europe Hope Rises; ISM Services Index Falls - NASDAQ 12.05.11 | 05:12 pm
- Zacks #5 Rank Additions for Friday - Tale of the Tape - Zacks 11.11.11 | 09:11 am
- Options Brief: Affymax - Benzinga 08.09.11 | 01:08 pm
- Future Biotech Superstars - Seeking Alpha 03.30.11 | 09:03 am
- Affymax Announces Decision in Arbitration Against JNJ - Benzinga 10.06.10 | 04:10 pm
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 10.05.10 | 09:10 am
